Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions
Ming‐Lung Yu(National Sun Yat-sen University), Ding‐Shinn Chen(Nanyang Institute of Technology), Chen‐Hua Liu(National Taiwan University Hospital), Rong‐Nan Chien(Chang Gung Memorial Hospital), Jee‐Fu Huang(Kaohsiung Medical University), Pei‐Jer Chen(National Taiwan University), Chung‐Feng Huang(Kaohsiung Medical University), Jia‐Horng Kao(National Taiwan University Hospital), Cheng‐Yuan Peng(China Medical University), Yi‐Hsiang Huang(First Hospital of Lanzhou University), Chun‐Jen Liu(National Taiwan University), Chun‐Yen Lin(Chang Gung University), Pin‐Nan Cheng(National Cheng Kung University Hospital), Chao‐Hung Hung(Chang Gung University), Chien‐Wei Su(National Yang Ming Chiao Tung University), Shih‐Jer Hsu(National Taiwan University Hospital), Wan‐Long Chuang(Kaohsiung Medical University)
Cited by 11
Related Papers
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
A proposed system for the nomenclature of hepatitis C viral genotypes
|Hepatology|1994|1k
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653